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Abstract
Background: Epilepsy belongs to a group of chronic and highly heterogeneous brain 
disorders. Many types of epilepsy and epileptic syndromes are caused by genetic 
factors.
The neural amino acid y-aminobutyric acid (GABA) is a major inhibitory neurotrans-
mitter in the mammalian central nervous system. It regulates activity of channel pores 
by binding to transmembrane GABA-receptors (GABRs). The GABRs are heteropen-
tamers assembled from different receptor subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π, and 
ρ1-3). Several epileptic disorders are caused by mutations in genes encoding single 
GABRs.
Methods: We applied trio- and single-whole exome sequencing to search for genetic 
sequence variants associated with a wide range of epileptic phenotypes accompanied 
by intellectual disability and/or global developmental delay in the investigated patients.
Results: We identified four hemizygous sequence variants in the GABAA receptor sub-
unit ε gene (GABRE), including one nonsense (NM_004961.3: c.399C>A, p.Tyr133*), 
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1 |  INTRODUCTION
The International League Against Epilepsy (ILAE) defined 
epilepsy as a prevalent and highly heterogeneous disorder of 
the brain (Fisher et al., 2014). This disorder leads to seizures, 
defining sudden erroneous and unprovoked electrical con-
ductions between neurons (Guerreiro,  2016). The ILAE an-
nounced a three-level classification system for epileptic seizure 
types, epilepsy types, and epileptic syndromes that support a 
better clinical diagnosis and treatment of patients affected with 
epilepsy (Chang, Leung, Ho, & Yung, 2017). Among epilep-
tic seizure types three major groups can be distinguished: (a) 
focal onset seizures derived from neuronal networks which 
are exclusively restricted to an unilateral brain hemisphere, 
(b) generalized onset seizures which originate from bilateral 
neuronal networks, and (c) idiopathic epilepsies without any 
evident etiology, frequently showing genetic predispositions 
(Berg et al., 2018; Chang et al., 2017; Guerreiro, 2016; Hirose, 
Mitsudome, Okada, & Kaneko, 2005). Additionally, epileptic 
disorders were classified into genetic, structural, metabolic, and 
unknown origin (Berg et al., 2010; Korff & Scheffer, 2013).
Genetic factors play an important role in many types of ep-
ilepsy and epileptic syndromes, often in these with unknown 
origin (Nieh & Sherr,  2014). Despite of a fast development 
in bio-medical technologies and advances in next generation 
sequencing (NGS), resulting in a substantial progress in the 
discovery of genes and/or multiple-loci associated with epi-
leptic disorders, many of the genotype-phenotype correlations 
remain to be elucidated (Symonds, Zuberi, & Johnson, 2017). 
It has been previously reported that certain forms of epilepsy 
can be caused by pathogenic variants in several distinct gam-
ma-aminobutyric acid receptor (GABR) subunit genes (Butler 
et al., 2018; Hernandez et al., 2016b; Ishii et al., 2017; Shen 
et al., 2017). GABA is the major inhibitory neurotransmitter 
in the mammalian central nervous system (CNS), involved in 
numerous developmental processes in the brain (Macdonald 
& Olsen, 1994; Watanabe, Maemura, Kanbara, Tamayama, & 
Hayasaki, 2002). It is involved in neural migration, facilitates 
extension of neurites, and plays an important role in a synap-
tic maintenance (Behar et al., 1994; Behar, Schaffner, Scott, 
O'Connell, & Barker, 1998; Watanabe et al., 2002). About 20% 
of neurons in the CNS are GABAergic (Watanabe et al., 2002). 
GABRs are pentameric, ligand-gated chloride channels, com-
posed of a combination of different subunits (α1-6, β1-3, γ1-3, 
δ, ε, θ, π, and ρ1-3; Hernandez et al., 2016b; Macdonald & 
Olsen, 1994; Watanabe et al., 2002). Each GABR subunit is 
composed of a large extracellular N-terminal domain, four 
hydrophobic transmembrane domains, and a large intracellu-
lar domain, which is the most heterogeneous part of a single 
receptor (Moss & Smart, 2001). Ionotropic GABRs are clas-
sified based on their pharmacology into two types of recep-
tors: GABAA and GABAC (Moss & Smart,  2001). GABAA 
receptors are important targets of drugs, including benzo-
diazepines, barbiturates, and other neuroactive medications 
(Sieghart,  2000). Pathogenic variants in genes encoding for 
several GABAA receptor subunits are known to cause epi-
lepsies of different severity, from mild febrile seizures to se-
vere epileptic encephalopathies (Carvill et al., 2014; Cossette 
et  al.,  2002; Hernandez et  al.,  2016b; Kodera et  al.,  2016; 
Moller et al., 2017; Shen et al., 2017). The majority of mono-
genic pathogenic variants are associated with GABRA1, 
GABRB2/3, and GABRG2 genes, which form the abundant 
α1β2/3γ2 subtype of GABAA receptors in the CNS (Farrant 
& Nusser, 2005). Unlike many GABAA receptors, those con-
taining the ε subunit have restricted distributions, form func-
tional channels with distinct pharmaco-biochemical activities 
and lead to spontaneous channel opening with slowed recov-
ery (Neelands, Fisher, Bianchi, & Macdonald, 1999; Wagner, 
Goldschen-Ohm, Hales, & Jones, 2005). The assembly of the 
ε subunit into GABAA receptors and its complete biological 
function is poorly understood (Bollan, Baur, Hales, Sigel, 
& Connolly,  2008). So far, only a few variants of unknown 
two missense variants (NM_004961.3: c.664G>A, p.Glu222Lys; NM_004961.3: 
c.1045G>A, p.Val349Ile), and one variant affecting the translation initiation codon 
(NM_004961.3: c.1A>G, p.Met1?) in four unrelated families.
Conclusion: Our clinical and molecular genetic findings suggest that GABRE is a 
likely candidate gene for epilepsy. Nevertheless, functional studies are necessary to 
better understand pathogenicity of the GABRE-mutations and their associations with 
epileptic phenotypes.
K E Y W O R D S
exome sequencing, GABA receptor type A subunit epsilon, GABRE, genetic epilepsy, novel 
sequence variants
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significance in the GABAA receptor subunit ε gene (GABRE, 
OMIM: 300093) have been reported in single epilepsy-cases 
(Butler et al., 2018; Hernandez et al., 2016b; Wang, Du, et al., 
2017).
Herein, we present four novel hemizygous sequence vari-
ants identified in the GABRE gene, including nonsense (n = 1), 
missense (n = 2), and translation initiation codon (n = 1) vari-
ants, in unrelated patients manifesting various epileptic pheno-
types. Our clinical and genetic findings extend the current set 
of known genes related to genetic epilepsies (GEs) and neuro-
developmental disorders. This will lead to a better understand-
ing of pathogenic mechanisms underlying these devastating 
neurological, frequently life-threatening conditions, and may 
also contribute to the development of improved antiepileptic 
drug-based therapies in the future.
2 |  MATERIAL AND METHODS
2.1 | Clinical data of patients and ethical 
compliance
GE affected patients (P1, P2, P3, and P4) and their avail-
able family members were referred to the Human Genetics 
at the University of Oldenburg (Oldenburg, Germany), CHU 
de Bordeaux, Hospices Civils de Lyon (Lyon, France), and 
Erasmus MC University Medical Center (Rotterdam, the 
Netherlands). All examined relatives of P1 originated from 
Germany, whereas P2, P4, and their relatives originated from 
France. The family of P3 settled in the Netherlands, but the 
grandparents of this patient were of Russian Caucasian ori-
gin. The patients and their relatives were informed about pos-
sible consequences of the study, agreed to participate in the 
study, and signed informed written consents before the pro-
ject started. The study adhered to the tenets of the Declaration 
of Helsinki and was approved by local ethics committees 
(Hannover Medical School (MHH) ethics committee, OE9515; 
Medizinische Ethik-Kommission University Oldenburg, 
Comité de protection des personnes Bordeaux- Outre Mer III, 
France; Erasmus MC, METC-2012387).
2.2 | DNA extraction
Peripheral blood samples from the patients and their available 
family members were collected in EDTA tubes. DNA isola-
tions were performed according to the manufacturer's recom-
mendations using either Gentra Puregene Kit (QIAGEN) or 
Nucleon BACC3 (GE Healthcare) or Tecan EVO workstation 
(Promega). DNA quantity and quality were measured using, 
either Biospectrometer (Eppendorf) or Qubit® Fluorometer 
(Thermo Fisher Scientific) or NanoDrop spectrophotometer 
(Thermo Fisher Scientific).
2.3 | Whole exome sequencing (WES)
A total of 50 ng of genomic DNA (gDNA) from P1 was used 
for an enzymatic fragmentation/ligation and enrichment of ex-
omic sequences using TruSeq® Rapid Exome Kit (Illumina). 
DNA libraries obtained from gDNA of P1 were 3-plexed with 
two different DNA libraries that were not included in this 
study. A pair-end sequencing (2 × 75 bp) using NextSeq™ 
500 Mid Output Kit was conducted with the NextSeq500 sys-
tem (Illumina). Demultiplexing and processing of WES data, 
together with variant calling, and annotation were performed 
using Varvis™ bioinformatics platform (Limbus Medical 
Technologies GmbH) based on the human genome build 
(hg19/GRCh37). High and moderate impact genetic sequence 
variants were filtered for allele frequency (AF) below 1.5% re-
ported in Exome Aggregation Consortium (ExAc, https://gno-
mad.broad insti tute.org/) and Genome Aggregation Database 
(GnomAD, https://gnomad.broad insti tute.org/). The sequence 
variants following X-linked and autosomal recessive modes of 
inheritance were considered for further analyses. Sequencing 
reads encompassing selected sequence variants were addition-
ally evaluated with Integrated Genomics Viewer (IGV, http://
softw are.broad insti tute.org/softw are/igv).
Trio-WES analysis was performed for family 2, includ-
ing P2 and unaffected parents. Preparation of gDNA librar-
ies, exome capture, sequencing, and data analysis were made 
with IntegraGen SA (IntegraGen SA), using SureSelect XT 
Clinical Research Exome in-solution enrichment methodology 
(Agilent technologies, Santa Clara, California, USA). Paired-
end sequencing runs (2 × 75 bp) were performed on Illumina 
HiSeq4000 (Illumina). The detailed explanations of the pro-
cess have been previously described (Gnirke et al., 2009). A 
bioinformatic pipeline, including base calling was performed 
for each WES data using the Real-Time Analysis software ver-
sion 2.7.7 (Illumina) sequence pipeline with default parame-
ters. Sequence reads were mapped to the hg19/GRCh37 using 
Elandv2e (CASAVA1.8.2; Illumina), and duplicated reads 
were removed. Furthermore, CASAVA1.8.2 was used to call 
single-nucleotide variants (SNVs) and short insertions/dele-
tions (max. size is 300 bp). Variants’ filtering was performed 
on Eris v3.0 (IntegraGen SA). Only variants with an appro-
priate familial segregation were considered, under the hy-
pothesis of an autosomal recessive, X-linked and a dominant 
disease with de novo germinal pathogenic variants. Variants 
with minor allele frequency (MAF) ≥1.5% in ExAc as well 
as noncoding variants were not included into further analyses. 
Finally, mapped reads were visualized with Alamut Visual 
Software 2.9.0 (Interactive Biosoftware).
Trio-WES was applied in family 3 using the Agilent Sure 
Select platform (Clinical Research Exome V2). A 150 bp paired-
end sequencing run was performed on HiSeq4000 (Illumina). 
Sequencing data were demultiplexed by CASAVA software 
(Illumina) and reads were mapped to the hg19/GRCh37 by 
4 of 13 |   MARKUS et Al.
Burrows-Wheeler Aligner (http://bio-bwa.sourc eforge.net/). 
Variants were detected with Genome Analysis Toolkit (http://
www.broad insti tute.org/gatk/). Subsequently, sequence vari-
ants were filtered with Cartagenia software package (Agilent 
Technologies), considering reads’ quality (read depth ≥10), 
MAF ≤ 1.5% (dbSNP, ESP6500, the 1,000 Genome project, 
GoNL, or the ExAc database), and location (within an exon 
and 10 bp areas encompassing introns). Variants were further 
selected in regard to an autosomal recessive, X-linked or de 
novo dominant inheritance.
Trio-WES analyses of family 4 using DNA samples from 
P4 and healthy parents were performed on a HiSeq 1000 
Sequencing System (Illumina). The sequencing was done with 
a 2 × 150 bp high output sequencing kit after enrichment with 
SeqCap EZ MedExome kit (Roche), according to manufactur-
er's specifications. Sequence quality was assessed with FastQC 
0.11.5 (Babraham Bioinformatics). After sequencing, reads 
were mapped to the hg19/GRCh37, using BWA-MEM (http://
bio-bwa.sourc eforge.net), sorted and indexed (Samtools, 
http://samto ols.sourc eforge.net). Duplicates were flagged 
(Sambamba, https://www.open-bio.org/wiki/Sambamba) 
and coverage was calculated (Picard-Tools, https://broad insti 
tute.github.io/picar d/). Variant calling was performed with 
GATK 3.7 Haplotype Caller (https://gatk.broad insti tute.org/
hc/en-us) and variants were annotated with SnpEff (http://
snpeff.sourc eforge.net/), dbNSFP (http://sites.google.com/
site/jpopg en/dbNSFP), GnomAD, ClinVar (https://www.
ncbi.nlm.nih.gov/clinv ar/), Human Gene Mutation Database 
(HGMD), Variome Great Middle East (http://igm.ucsd.edu/
gme/data-brows er.php) Mutation Tester (http://www.mutat 
ionta ster.org/), Combined Annotation Dependent Depletion 
(CADD, https://cadd.gs.washi ngton.edu/), as well as with an 
in-house-database.
2.4 | Primers, PCR amplification and 
Sanger sequencing
Sanger sequencing was performed in family 1. Primers 
(fwd_5’-TAAGAGAGGCAAGGTCCCAC, rev_5’-CTTG-
GCAAAGCACTTACTTCTT) located in intronic regions 
of the human GABRE gene (NM_004961.3) and encompass-
ing exon 6 were designed using Primer Input3 (http://prime 
r3.ut.ee/). They were additionally verified for common SNPs 
using SNPCheck (https://secure.ngrl.org.uk/SNPCh eck/). 
In total, 10  ng of gDNA samples from P1 and from unaf-
fected relatives (including parents, sister, and grandfather 
from maternal side) were used for PCR amplification with 
HotFirePol DNA Polymerase (Solis BioDyne), according to 
manufacturer's recommendations (Figure  1a; Figure  S1a). 
Afterward, the amplicons were purified using enzymati-
cal ExoI-SAP method (New England Biolabs) and bilater-
ally sequenced using the BigDye® Terminator v3.1 Cycle 
Sequencing Kit on the ABI Prism 3130xl Genetic Analyzer 
(Applied Biosystem). Sanger sequencing data were analyzed 
with SeqScape software (Applied Biosystem) and SnapGene 
software (GSL Biotech).
Results of high throughput sequencing from P2, P3, and 
P4 were not additionally verified by Sanger sequencing as 
the GABRE gene, especially the nucleotide positions of the 
F I G U R E  1  Analysis of identified hemizygous variants in GABRE in unrelated patients. (A) Family P1 includes healthy parents (I.I, I.II), one 
female healthy child (II.I), and the GE-affected child (P1, II.II). The father (I.I) showed the hemizygous reference sequence, while the mother (I.II) 
and the sister (II.I) were carriers of the missense variant NM_004961.3: c.664G>A. (B) Family P2 consists of healthy parents (father I.I, mother 
I.II), one male healthy child (II.II) and one affected child (P2, II.I, NM_004961.3: c.1A>G). The other members of this family are healthy. (C) 
Family P3 includes the healthy parents (father I.I, mother I.II) and two children, the healthy daughter (II.I) and P3 (II.II), who showed a C-to-A 
substitution, leading to a premature termination codon (NM_004961.3: c.399C>A). The other members of family P3 were healthy. (D) Family 
P4 consists of healthy parents (father I.II, mother I.II) and one affected child (P4, II.I, NM_004961.3: c.1045G>A). No relevant familial history 
was noted. All variants were detected using WES and reads were obtained from both directions, forward and reverse. Symbols: squares = males; 
circles = females; black solid squares with arrows = patients affected with epilepsy; solid white icons = healthy individuals; icons with 
dot = known carrier
(a) (b) (c) (d)
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identified pathogenic sequence variants were very well cov-
ered in the trio-WES data.
2.5 | Multiple species protein alignments and 
in silico predictions of GABRE protein domains
Multiple sequence alignments were performed with the 
ClustalW2 tool (http://www.ebi.ac.uk/Tools /msa/clust 
alw2/). Amino acid sequences of GABRE proteins were 
compared between human (GenBank: NP_004952.2), 
mouse (GenBank: NP_059065.2), Norway rat (GenBank: 
NP_075579.1), rabbit (GenBank: XP_002721372.1), hedge-
hog tenrec (GenBank: XP_004715681.1), Sunda flying lemur 
(GenBank: XP_008589892.1), dog (GenBank: XP_549340.3), 
Californian Sea Lion (GenBank: XP_027465429.1), Chinese 
rufous horseshoe bat (GenBank: XP_019566807.1), and lesser 
ferret (GenBank: XP_004776709.1).
Publicly available tools to predict protein domains, such as 
NCBI Conserved Domain Search (https://www.ncbi.nlm.nih.
gov/Struc ture/cdd/wrpsb.cgi), PROSITE (http://prosi te.ex-
pasy.org), and SMART (http://smart.embl-heide lberg.de) were 
used to in silico estimate locations of the mutated amino acids 
in the GABRE protein, found in our patients.
Additionally, MetaDome data (https://github.com/cmbi/
metadome) were used to predict pathogenicity and improve 
interpretation of the newly identified GABRE-variants. 
MetaDome aligns information of population variations from 
the ExAc and pathogenic variants from the HGMD with Pfam 
protein domains. Generally, MetaDome visualizes meta- 
domain information and gene-wide profiles of genetic tol-
erance based on 56’319 human transcripts, 71’419 protein 
domains, 12’164’292 genetic variants from GnomAD, and 
34’076 pathogenic variants from ClinVar (Wiel et al., 2019).
3 |  RESULTS
3.1 | Clinical features of epilepsy-affected 
patients
P1 is a 5 ½ years old boy and the only affected child of non- 
consanguineous parents (Figure S1a). Pregnancy and birth at 
term were normal (birth weight 3,905 g, body lengths 53 cm, 
head circumference 39.0 cm). Apgar values were normal with 
9-10-10. Myoclonic jerks were observed at the age of 4 weeks. 
The first electroencephalography (EEG) was performed at the 
age of 8  weeks and showed no epileptic discharges. At the 
age of 3 months P1 was transferred to University Children's 
Hospital, Klinikum Oldenburg, Oldenburg because of in-
creased infantile spasms. Because EEG showed hypsarrhyth-
mia the West syndrome was diagnosed in P1. Extensive 
diagnostic investigations, including cerebral magnetic 
resonance imaging (MRI), metabolic examinations with cer-
ebrospinal fluid examination with neurotransmitter analy-
sis, genetic array comparative genomic hybridization (array 
CGH), and panel diagnostic for epileptic encephalopathies (79 
genes) were performed. However, no abnormalities were de-
tected. An extended antiepileptic therapy over the next years 
with 11 different antiepileptic drugs and a ketogenic diet were 
applied. However, these treatments did not give any long-
lasting positive therapeutic effects and the patient was finally 
diagnosed with pharmaco-resistant epilepsy of the West syn-
drome type (Table 1, P1). Recently, (at the age of 5 ½ years) 
P1 was treated with valproic acid, sulthiame, and cannabidiol. 
Renew EEG examinations showed a too slow basic rhythm, 
bioccipital delta waves, multifocal sharp- and sharp-slow-
waves predominantly from temporo-parietal. Furthermore, P1 
showed a strong abnormal psychomotor development. At the 
age of 5½ years P1 was unable to fix or follow objects with his 
eyes, he was unable to grasp, to turn around or to sit freely. He 
was not able to spell out and understand any words. The head 
circumference declined over the time and the patient devel-
oped a microcephaly (48 cm, first percentile, −2.9 SD). MRI 
examinations were additionally performed at the age of 4 and 
7 months, and 3 and 4 years. MRI findings revealed a progres-
sive global cerebral atrophy.
P2 is 21 years old and the only affected child in a non- 
consanguineous family. There is a familial history of intel-
lectual deficiency in the maternal branch, with multiple male 
affected with intellectual disability (Figure  S1b). P2 was 
born at term after an uneventful pregnancy. He presented 
global developmental delay, was able to sit alone at the age 
of 10 months and walked at the age of 30 months. Mild static 
and kinetic ataxia were observed since the age of 3 years, and 
remained stable over years. He presented partial complex epi-
leptic seizures with temporal abnormalities on EEG at the age 
of 6 years (Table 1). He was effectively treated with valproic 
acid, levetiracetam, and topiramate, showing normal EEGs 
at the age of 10 years. He also had a bicuspid aortic valve 
and small initial aorta dilatation, treated with bisoprolol. 
Dilatation remained stable over years. Hyperprolinemia was 
noted during an amino acid chromatography testing, which 
was treated with riboflavin. He followed adapted courses 
during childhood and was finally referred to a center for dis-
abled persons.
P3 is a 21-year-old man and one of two children of unre-
lated parents (Figure S1c). He was born at a gestational age 
of 42 weeks with a birth weight of 3,850 g. P3 pronounced 
his first words at the age of 1.5  years, in a context of bi-
lingualism (Dutch and Russian). Initial concerns appeared 
around the age of 2 years, with hyperactive behavior at the 
age of 3 years. He also manifested speech delay, and autistic 
behaviors. Intelligence quotient (IQ) testing revealed an IQ 
score of 55. At the age of 18 years he had a first tonic-clonic 
seizure, without clearly provoking factors. He was treated 
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with valproic acid, levetiracetam, and carbamazepine. A val-
proic acid medication alone was insufficient to control his 
epilepsy (Table 1). To improve attention abilities and better 
control behavioral disturbances the patient was additionally 
treated at the age of 8 years with risperidone and methylphe-
nidate. He did not show any visual or auditive impairment. 
Physical examination identified dysmorphic signs, similar to 
Marfanoid habitus, with narrow and high palate, long and 
slender fingers with slight camptodactyly, mild pectus exca-
vatum, and stretch marks on the chest, shoulder, and lower 
back.
P4 was 10 years old at the time of the study. He was born 
after an uneventful pregnancy (Figure  S1d). He presented 
global developmental delay during childhood and manifested 
behavior troubles. He suffered from focal to bilateral seizures 
since the age of 3 years (Table 1). EEG-measurements showed 
highlighted spikes in contralateral hemisphere as well as bilat-
eral wave discharges. He was treated with sulthiame and cloba-
zam. Brain MRI examination did not detect any abnormalities. 
He also presented hypothyroidism.
3.2 | Sequencing analyses
The DNA library from P1 was multiplexed with two differ-
ent DNA libraries, which were not subjected to the project. 
The 3-plex sequencing run resulted in 31.8 Gb raw data and 
showed a Q30-score of 87%, cluster density of 336 K/mm2, 
and cluster passing filter of 74.9%. Size of sequencing data 
obtained from P1 was estimated to 6.70  Gb, generating 
66.86  M of clusters, 133.72  M of reads, and 92.5% of 10× 
targeted coverage. Applying stringent selection settings, the 
initial number of genetic variants was reduced to 90. We veri-
fied these variants for plausible types of inheritance, including 
autosomal-recessive and X-linked. Only one genetic variant 
passed the filtering criteria of X-linked mode of inheritance. 
The remaining 89 variants were excluded either due to an in-
correct inheritance pattern or misguided disease-associations. 
We also considered heterozygous variants for possibly being 
de novo variants. None of these heterozygous variants was 
found in a promising candidate gene, to further verify its po-
tential de novo appearance in familiar co-segregation analyses 
F I G U R E  2  Identification of sequence variations in the GABRE gene in 4 GE-affected patients. (A and B) X-chromosomal localization of the 
human GABRE gene and its distribution of exons. (C) We found variants in exon 1, 4, 6, and 8, located in different protein domains. (D) Multiple 
species sequence alignments of GABRE proteins. The mutated GABRE protein sequences of the patients described herein were shown on top 
of the alignments. Consensus symbols in the alignments represent: aa, amino acid; SP, signal peptide; LCR, low complexity region; LBD, Pfam 
Neurotransmitter-gated ion-channel ligand binding domain; memb, Pfam Neurotransmitter-gated ion-channel transmembrane region; (x), single; 
fully conserved residues; (:), strongly similar residues; (.), weakly similar residues; (−), lack of identity between residues
(a)
(b)
(c)
(d)
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with Sanger sequencing (Table S2). According to the hg19, 
this genetic variant was located on X-chromosome, at posi-
tion 151’128’431. It was a missense variant (NM_004961.3: 
c.664G>A, NP_004952.2: p.Glu222Lys) located in exon 6 of 
the GABRE gene (Figures 1 and 2). Out of a total of 28 aligned 
reads, 22 were sequenced from a reverse direction, whereas 
6 reads were shown from a forward direction. All sequenced 
reads contained the G-to-A exchange at the nucleotide posi-
tion 664 (Figure 1a). The allele frequency of the c.664G>A 
(NM_004961.3) substitution, was estimated to 0.00004409 
ExAc (Table  S1). In silico predictions of the glutamic acid 
into lysine substitution at the amino acid position 222 in the 
GABRE protein suggested a likely pathogenic variant and 
showed M-CAP = 0.387 and SIFT = 0.78 (VARVIS Version 
1.12; Limbus Medical Technologies GmbH). Sanger sequenc-
ing was additionally performed in P1 and the available family 
members. The analyses confirmed the co-segregation of the 
c.664G>A (NM_004961.3) variant in the GABRE gene in the 
family of P1 (Figure 1a; Figure S1a).
In family 2, a trio-WES was performed. The sequenced 
data for P2 resulted in 9.69  Gb raw data and showed Q30-
score of 97%, and 95% of bases were covered at 25×. After 
variant filtering, only one variant was identified as a potential 
candidate for GE (Table S2). This variant was located on the 
X-chromosome at position 151’974’625. The sequence variant 
was detected in exon 1 of the GABRE gene and was thought 
to affect the translation initiation codon (NM_004961.3: 
c.1A>G, NP_004952.2: p.Met1?). Out of 63 aligned reads, 
42 were sequenced from a reverse direction, whereas 21 reads 
were shown from a forward direction. The allele frequency 
of this sequence variant was estimated to 0.00001550 (ExAc, 
Table S1). The single A-to-G substitution at nucleotide 1 of 
F I G U R E  3  Schematic presentation of pathogenicity predictions and localization of variants in the GABRE protein. (A) Landscape of the 
localization of the novel and previously identified variants in the GABRE gene and their predicted tolerance in the specific regions of the GABRE 
protein performed with MetaDome (NM_004961.3, NP_004952.2). Red areas represented highly intolerant regions, whereas blue regions showed 
highly tolerant areas. (B) The newly identified GABRE-variants are presented as red arrows (P2, NP_004952.2: p.Met1?; P3, NP_004952.2: 
p.Tyr133*; P1, NP_004952.2: p.Glu222Lys, intolerant; P4, NP_004952.2: p.Val349Ile, slightly intolerant). The previous GABRE-variants reported 
by Hernandez et al., 2016 (a1: p.Arg452Gly, intolerant; b: p.Arg472His, tolerant, and c: p.Ser484Leu, neutral) and by Wang, Du, et al., 2017  
(a2: p.Arg452Leu, intolerant) are shown as white arrows. TM, transmembrane region (TM1: aa 254-274; TM2: aa 281-301; TM3: aa 344-364; TM4 
aa 486-506); aa, amino acid; N, N-terminus; C, C-terminus; LBD, Pfam Neurotransmitter-gated ion-channel ligand binding domain; memb, Pfam 
Neurotransmitter-gated ion-channel transmembrane region.
(a)
(b)
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the GABRE gene in P2 was predicted to likely cause an al-
ternative initiation codon. This substitution was found in 
all sequencing reads. The translation initiation codon ATG 
(coding for methionine) was changed to GTG (coding for 
valine). Consequently, this variant was predicted to result in 
an abnormal length of the GABRE protein (NP_004952.2: 
p.Met1?). This variant co-segregated with the GE phenotype 
within the family (Figure 1b).
A gene-panel approach for intellectual disabilities that was 
initially applied in P3 did not reveal any obvious causative vari-
ants. Therefore, trio-WES was considered to further search for 
the molecular cause of GE in P3. Around 95% of sequencing 
reads from each WES showed a coverage of 10×. Simultaneous 
analyses of WES data for P3 and his healthy parent revealed 
a nonsense variant in the GABRE gene (NM_004961.3: 
c.399C>A, NP_004952.2: p.Tyr133*). P3 was hemizygous for 
the mutated allele, whereas his mother was a carrier, and the 
father showed the reference allele (Figure 1c).
Variant filtering was applied in P4 and his healthy par-
ents. A hemizygous missense variant, located in exon 8 of 
the GABRE gene was only found in P4, whereas the mother 
was carrier for this variant. As expected, the unaffected father 
showed reference allele (Figure 1d). The identified GABRE-
variant in P4 was predicted to lead to an exchange of valine 
into isoleucine (NM_004961.3: c.1045G>A, NP_004952.2: 
p.Val349Ile) and was not found in the ExAc/GnomAD data-
base. SIFT score and Mutation Tester showed scores of 0.92 
and 0.947, respectively (Table S1). The score of the CADD 
was estimated to 6.512. These predictions support the patho-
genicity of the variant in the GABRE gene detected in P4. In 
total, 20 x coverage of each WES was obtained for about 93% 
of sequencing reads.
3.3 | Bioinformatic predictions of the 
identified variants in the GABRE protein
To evaluate the evolutionary conservation of the GABRE 
protein, multiple protein alignments of different species were 
performed and showed a full conservation at amino acid 1, 
133, 222, and 349 in regard to the human reference protein 
(NP_004952.2; P2, P3, P1, P4; Figure 2).
In silico predictions of the GABRE protein domains re-
vealed that the genetic variants identified in P1 (NP_004952.2: 
p.Glu222Lys) and P3 (NP_004952.2: p.Tyr133*) were both 
located in the neurotransmitter-gated ion-channel ligand 
binding domain (PF02931; Figures 2c and 3b). This protein 
domain plays an important role in ligand binding, which in 
turn leads to changes in protein conformation and channel 
opening (Richter et al., 2012). The inflow of chloride into the 
cell is thought to result an inhibitory postsynaptic potential. 
The variant identified in P2 (NP_004952.2: p.Met1?) was lo-
cated at the signal peptide site of the GABRE protein, which 
determines the localization and the transport pathway of the 
protein within the cell (Blobel, 1980). The missense variant 
found in P4 (NP_004952.2: p.Val349Ile) was mapped to the 
neurotransmitter-gated ion-channel transmembrane region do-
main (PF02932). This protein domain is essential for ion chan-
nel formation (Figures 2c and 3b; Chen et al., 2018).
Tolerance analyses of the missense variants described 
herein (NM_004961.3: P1 c.664G>A, NM_004961.3: P4 
c.1045G>A) revealed that the mutated amino acids were lo-
cated in functional regions of the GABRE protein with intol-
erant and slightly intolerant impacts (Figure 3a). Moreover, we 
also tested the impact of previously reported missense variants 
(NP_004952.2: p.Arg452Leu, NP_004952.2: p.Arg452Gly, 
and NP_004952.2: p.Arg472His) in GABRE (Hernandez 
et al., 2016a; Wang, Du, et al., 2017). The two variants located 
at arginine 452 were predicted to be intolerant, while substi-
tutions at arginine 472 and at serine 484 were predicted to be 
highly tolerant or neutral, respectively (Figure 3b). These com-
putational analyses of variants allow us to better understand 
the possible pathogenicity of the GABRE-variants.
4 |  DISCUSSION
Hereditary epilepsies belong to a prevalent and highly hetero-
geneous group of brain disorders (Fisher et al., 2014). They 
lead to sudden, erroneous and unprovoked electrical currents 
in neuronal networks and are frequently caused by pathogenic 
variants in many different genes (Guerreiro, 2016; Wang, Lin, 
et al., 2017).
In this study, we identified four families with four novel 
sequence variants in the GABRE gene, including one nonsense 
(P3: NM_004961.3: c.399C>A, NP_004952.2: p.Tyr133*), 
two missense variants (P1: NM_004961.3: c.664G>A, 
NP_004952.2: p.Glu222Lys; P4: NM_004961.3: c.1045G>A, 
NP_004952.2: p.Val349Ile), and one affecting a translational 
initiation codon (P2: NM_004961.3: c.1A>G, NP_004952.2: 
p.Met1?) in unrelated patients with GEs.
The GABAergic signaling is a major biological pathway 
and its abnormal regulation in neurons is known to be asso-
ciated with numerous CNS disorders (Kang,  2017; Kumar, 
Sharma, Kumar, & Deshmukh, 2013). Pathogenic variants in 
GABAA receptor subunit genes, including GABRA, GABRB, 
and GABRG, impair GABAergic signaling via postsynaptic 
mechanisms that lead to GEs (Butler et al., 2018; Kang, 2017). 
Electrophysiological and biochemical studies suggested that 
the majority of pentamer receptors are composed of two α sub-
units, two β subunits, and a single γ subunit (Y. Chang, Wang, 
Barot, & Weiss, 1996; Tretter, Ehya, Fuchs, & Sieghart, 1997). 
This assembly of GABAA subunits is frequently found in a 
human brain (Bollan et al., 2008). The ε subunit seems to be 
evolutionary related to the γ subunit, showing an identity of 
amino acid restudies above 40% (Davies, Hanna, Hales, & 
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Kirkness, 1997). It has been speculated that the ε subunit is 
capable of replacing the γ subunit in the GABR pentamer, in 
order to form functional channels with distinct pharmacological 
and biophysical properties (Davies, Kirkness, & Hales, 2001; 
Saxena & Macdonald, 1994). This notion is supported by the 
finding that a replacement of α1 at the first position or β2 at 
the fourth position in the subunits’ assembly also resulted in 
functional channel pores (Bollan et al., 2008). Previous stud-
ies have further shown that pathogenic variants in α, β, and 
γ subunits significantly impair structures and functions of 
GABAA receptors and lead to GEs (Hernandez et al., 2016b; 
Janve, Hernandez, Verdier, Hu, & Macdonald,  2016; Wang, 
Du, et al., 2017). The reported deleterious sequence variants 
have been mainly identified in N-terminal regions and trans-
membrane protein domains, emphasizing an important biolog-
ical function of these protein parts (Hernandez et al., 2016b). 
Interestingly, the GABRE sequence variants reported herein 
were also predicted to alter these protein regions supporting 
their involvement in GE.
Interactions of the ε subunit with α, β, and γ subunits 
are poorly understood and raise the question of their poten-
tial to form specific or unique neurotransmitter binding sites. 
To date, the impact of sequence variants located within the 
neurotransmitter-gated ion-channel ligand binding domain 
of ε subunits on a loss or gain of binding sites remains un-
clear. Unlike other GABR subtypes, the receptors containing 
a single ε subunit were described to act agonist-independent 
and to spontaneously lead to slower deactivation and recov-
ery of the receptors (Davies et al., 2001; Maksay, Thompson, 
& Wafford, 2003; Neelands et  al., 1999; Ranna, Sinkkonen, 
Moykkynen, Uusi-Oukari, & Korpi,  2006; Wagner 
et al., 2005). Pathogenic variants in a single α, β, and γ subunit 
of GABAA receptors showed negative effects on opening and 
closing of channel pores changing their structure and/or con-
ductive functions, and therefore, are thought to result in epilep-
tic phenotypes (Matsumoto & Ajmonemarsan, 1964; Prince & 
Wilder, 1967). Since pathogenic variants in the α1 subunit lead 
to GEs (Burgess et al., 2019; Hernandez et al., 2016b, 2019; 
Krenn et al., 2019), it is likely that an exchange of α1 with a 
mutated ε subunit will cause epileptic phenotypes.
It has been shown that various pathogenic variants in the 
same GE-associated gene may result either in different forms 
of neurodevelopmental disorders or cause a wide spectrum of 
epilepsies (Johannesen et al., 2016). In the patients described 
herein, we observed that sequence variants in the GABRE 
gene may cause a broad range of epileptic phenotypes, from 
an early-onset and severe pharmaco-resistant epileptic en-
cephalopathy to late-onset and mild forms of generalized 
and focal epilepsy (Table 1, Figure 3). Currently, only hand-
ful patients with GABRE-variants were described worldwide 
and only very little details were published about the clinical 
symptoms of these patients. So far, only one patients with a 
missense variant (NM_004961.3: c.1355G>A, NP_004952.2: 
p.Arg452Leu) in the GABRE gene was described to manifest 
infantile spasms, hypsarrhythmia, myelin development ab-
normalities, and brain dysplasia (Wang, Du, et al., 2017). We 
also found similar clinical symptoms in P1 affected with the 
West syndrome. Interestingly, most of the patients presented 
herein showed moderate forms of epilepsy with developmen-
tal delay and intellectual disability. These are novel clinical 
features that were unreported in patients having sequence 
variants in the GABRE gene (Hernandez et al., 2016b; Wang, 
Du, et al., 2017). Interestingly, a wide spectrum of epileptic 
phenotypes, ranging from early-onset severe forms, to late-on-
set mild forms, and to cases with intellectual disability and 
developmental delay with other neuropsychiatric symptoms 
were already reported in patients with mutations in other 
GABAA receptor subunit genes (Maljevic et al., 2019; Oyrer 
et al., 2018). However, due to a limited number of cases with 
sequence variants in the GABRE gene it is currently difficult 
to establish a clear phenotype-genotype correlation. Moreover, 
modifier variants located in uncovered coding and noncoding 
regions of known epilepsy-related genes, as well as variants 
in new genes, which cannot be excluded, may also impact 
on the phenotypic discrepancies observed in the investigated 
patients.
The available clinical data also suggested that the pa-
tients may respond differently to treatments with antiepilep-
tic drugs. Epileptic seizures in P3 and P4 were either under 
control or even fully silenced in P2 due to applied therapies. 
However, seizures were not treatable or diminished by med-
ications in P1, who showed pharmaco-resistant epilepsy. It 
has been reported that many GE-affected patients, similar to 
P1, did not respond to any drug therapies (Pierzchala, 2010). 
Consequently, epilepsies and epileptic syndromes remain 
life-threatening neurological disorders. An identification of 
new pathogenic variants in epilepsy-associated genes, and a 
discovery of novel candidate genes associated with epilepsies 
and neurodevelopmental disorders are essential for a deeper 
understanding of the genetic heterogeneity underlying these 
clinical symptoms. Additionally, in vitro and in vivo func-
tional studies will be essential to enable the understanding of 
the molecular functions and pathogenicity of identified se-
quence variants, and thus, will contribute to a development of 
treatment options.
In this study, we identified novel sequence variants in the 
GABRE gene in four unrelated patients affected with GEs. The 
previously described genomic studies on large cohorts of pa-
tients affected with different forms of GE independently de-
scribed four single cases with sequence variants in the GABRE 
gene (Hernandez et  al.,  2016b; Wang, Du, et al., 2017). 
However, the interpretation of these genetic findings was 
difficult due to the lack of comparable cases. Private patho-
genic variants or sequence variants of unknown significance 
could not be excluded. Our genetic and clinical findings ob-
served in P1 were similar to the previously reported case with 
   | 11 of 13MARKUS et Al.
GABRE-variant (Wang, Du, et al., 2017) emphasizing an asso-
ciation of sequence variants in the GABRE gene with GE. We 
also collected three patients with GABRE-variants showing 
milder epileptic phenotypes as well as developmental delay 
and intellectual disability. In summary, this is the first report 
that showed the wide variety of epileptic phenotypes in very 
rare patients with sequence variants in the GABRE gene.
We postulate that the GABRE gene is a likely candidate 
gene for epilepsies of different forms and severities. Our stud-
ies lay the grounds for a better understanding of novel mo-
lecular genetic factors related to these clinical features. They 
may also complement the current knowledge of pharmaco- 
biochemical activities of GABAA receptors and may be use-
ful to improve current therapies or develop novel antiepileptic 
drug treatments in the future.
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